With significant recent media and public attention on the role of GLP-1 agonist medications in weight management, health and wellbeing, we’re keen to equip members who may be receiving questions about these medications from their customers with information.
We also want to help you to understand what developments in this area mean for professionals in the sector and the impact that they may have on client outcomes.
This webinar provides technical insights into GLP-1 agonist therapies and information on the implications of these medications on health, wellbeing and fitness services.
The session also explores the composition of GLP-1 agonists, clinical support protocols and anticipated developments, and is designed to provide sector professionals with a baseline understanding of this type of medication and its potential applications.
Webinar highlights:
- In-depth overview of GLP-1 agonist medications and their composition
- Guidance on clinical support and potential integration strategies – Insights into trends and future developments
- Insights into trends and future developments
The session is led by CIMSPA’s Head of Insight and Business Transformation Phillip Wright, alongside an expert panel, including:
- Dr Morgan Toerien – Clinical Director, Bodyline Medical Wellness Clinics
- Natasha Eason – Associate Director – Education/Training Academy, CIMSPA
- Kenny Butler – Head of Health & Wellbeing Development, UK Active
- Jenny Patrickson – Managing Director, Active IQ
- Sally-Ann Turner – Managing Director, Bodyline Medical Wellness Clinics